|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Diabetic Nephropathy | |||||
| Chronic Kidney Disease Stages 3 & 4 | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Albuminuria | |||||
| Diabetic Nephropathies | |||||
| Kidney Diseases | |||||
| Kidney Failure, Chronic | |||||
| 3 | More general conditions related to this trial | ||||
| Diabetes Complications | |||||
| Diabetes Mellitus | |||||
| Endocrine System Diseases | |||||
| Kidney Failure | |||||
| Proteinuria | |||||
| Renal Insufficiency | |||||
| Renal Insufficiency, Chronic | |||||
| Signs and Symptoms | |||||
| Urination Disorders | |||||
| Urologic Diseases | |||||
| Urological Manifestations | |||||
| 4 | Interventions listed in this trial | ||||
| Zemplar (paricalcitol ) capsules | |||||
| Zemplar (paricalcitol) capsules | |||||
| Placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Ergocalciferols | |||||
| 6 | More general drug interventions related to this trial | ||||
| Bone Density Conservation Agents | |||||
| Growth Substances | |||||
| Micronutrients | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Vitamins | |||||
| 7 | Sponsors listed in this trial | ||||
| Abbott | |||||